ARCHER 1050: Dacomitinib versus Gefitinib in EGFR+ NSCLC

Viola Zhu, MD, PhD of UC Irvine Health gives an overview of the ARCHER 1050 trial in EGFR+ non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. <br /><br />Abst... Author: moasc Added: 08/02/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts